Advancing Efficacious MASH Therapeutics in the Evolving Metabolic Landscape 

Navigating Heterogeneous Patient Populations, Advancing Non-Invasive Biomarkers, & Delineating Combination & Sequential Therapies to Shape the Future of MASH Treatment From Discovery to Clinic

Driven by a surging pipeline, the MASH therapeutic landscape is radically transforming as more drugs reach clinical trials. While Madrigal's Rezdiffra marked a groundbreaking first approval, it also highlighted the vast scope for further, more comprehensive, patient-centered solutions. This is a pivotal moment to unlock unparalleled potential in conquering this widespread disease.

The 9th MASH Drug Development Summit is the essential forum for pharmaceutical giants and innovative biotechs dedicated to accelerating efficacious therapies for diverse patient populations. This year, we're diving deep into the game-changing potential of novel mechanisms of action, advanced biomarker integration, and strategic combination and sequential therapy regimens. Hear from titans such as Eli Lilly, AstraZeneca, Pfizer, and Takeda, alongside innovative biotechs such as Madrigal, Akero Therapeutics, 89 Bio, and more. Learn of the groundbreaking research and strategies focused on effective treatments through varied mechanisms and cell-targeting, accurate non-invasive biomarkers, patient-centered trial designs, and the profound potential of GLP-1s. The pressure is on to develop best-in-class treatments that transform patient lives.

Don't miss this pivotal opportunity to network with 60+ leading MASH scientists and drug development experts, forge crucial collaborations, and be part of the solution!

Collaborative atmosphere and knowledge sharing with different stakeholders working with one goal in mind to find therapies for MASH.

Novo Nordisk

MASH Drug Development Summit - Novo Nordisk

Explore the Full Event Guide

  • 60+ MASH Scientists & Drug Development Experts Sharing Groundbreaking Research & Strategies
  • 1 Pre-Conference Combination & Sequential Therapy Day
  • 10+ Hours of Networking with 60+ Likeminded MASH-Focused Peers
MASH drug development Brochure Cover

World-Class Speaker Faculty Includes:

MASH Drug Development Summit - Girish Rao

Girish Rao

Executive Director, Clinical Design- Cardiometabolic Health, Clinical Design Delivery & Analytics

Eli Lilly

MASH Drug Development Summit - Kevin Hart

Kevin Hart

Scientific Director

Pfizer

MASH Drug Development Summit - Rebecca Taub

Rebecca Taub

Chief Executive Officer

Madrigal

MASH Drug Development Summit - Reshma Shringarpure

Reshma Shringarpure

Vice President, Clinical Research & Medical Affairs

Akero Therapeutics

What to Expect

60+

MASH Leaders

9th

Year Running

23+

Speakers

10+

Networking Hours

Previously Attending Companies Include:

MASH Drug Development Summit - 89 bio
MASH Drug Development Summit - Akerobio
MASH Drug Development Summit - Astrazeneca
MASH Drug Development Summit - Bristol Myers Squibb
MASH Drug Development Summit - Daiichi Sankyo
MASH Drug Development Summit - GSK
MASH Drug Development Summit - Madrigal
MASH Drug Development Summit - Novo Nordisk
MASH Drug Development Summit - Sagimet Bio
MASH Drug Development Summit - Takeda

Official Partners

Antaros_Medical_logotype_RGB
Aragen_Logo_CMYK_Gradient
Perspectum_Logo
physio
MASH Drug Development Summit - Brochure Cover

Explore Related Events